About

About FIOCRUZ/Bio-Manguinhos The Institute of Technology in Immunobiologicals (Bio-Manguinhos) is the technical-scientific unit of the Oswaldo Cruz Foundation (Fiocruz) that produces and develops immunobiologicals to meet the demands of public health. Its product line consists of vaccines, reagent kits for laboratory diagnosis and biopharmaceuticals. Founded in 1976, Bio-Manguinhos is a reference in the sector and occupies a prominent position in the market. About Fiocruz/Bio-Manguinhos The Institute of Technology in Immunobiologicals (Bio-Manguinhos) is the technical-scientific unit of the Oswaldo Cruz Foundation (Fiocruz) that produces and develops immunobiologicals to meet the demands of public health. Its product line consists of vaccines, reagent kits for laboratory diagnosis and biopharmaceuticals. Founded in 1976, Bio-Manguinhos is a reference in the sector and occupies a prominent position in the market. The Institute of Technology on Immunobiologicals (Bio-Manguinhos) is the unit of the Oswaldo Cruz Foundation (Fiocruz) responsible for research, innovation, technological development and production of vaccines, in vitro diagnostics (IVDs), biopharmaceuticals and advanced therapies primarily aimed at meeting the demands of Brazilian Public Health System (SUS), besides providing technological services. The Institute also contributes with the public health of several countries, mainly by the supply of the yellow fever vaccine, pre-qualified by WHO. With 49 years of existence, it has become the largest federal laboratory in Latin America and has consolidated itself as a strategic agent of public health policies in Brazil, having been selected by WHO/OPAS as Hub for mRNA COVID-19 Vaccine production to Latin America and Caribbean. To keep up with the trends and best practices in the pharmaceutical industry, the investment in the expansion and modernization of infrastructure is constant, being part of the innovation process of Bio-Manguinhos. With its own technological development projects and partnerships, in addition to technology transfer agreements with public and private institutions, the Institute provides a range of products for the Brazilian Public Health System (SUS), through the programs of the Ministry of Health. In the period from 2019 to 2024, there were approximately 800 million doses of vaccines delivered to the National Immunization Program; more than 66 million reagent kits for laboratory diagnosis; and 35 million bottles/syringes of biopharmaceuticals. Bio-Manguinhos products guarantee free access to high-tech immunobiologicals by the Brazilian population and allow the reduction of expenses by the Ministry of Health. This leading role in the field of public health is the result of the commitment of 2,400 employees who make the difference in the lives of millions of people every day.